Definition
Cyclazocine is a synthetic opioid ligand that functions primarily as a κ‑opioid receptor (KOR) agonist and a partial agonist/antagonist at the μ‑opioid receptor (MOR). It has been investigated for its analgesic properties and for its potential to modulate the effects of other opioids.
Overview
Developed in the 1970s as part of a series of morphinan‑type compounds, cyclazocine was studied for its ability to produce analgesia while limiting typical μ‑opioid–mediated side effects such as respiratory depression and dependence. Clinical trials in humans demonstrated potent analgesic effects, but the drug also produced dysphoric and psychotomimetic reactions attributed to KOR activation, which limited its therapeutic acceptance. Consequently, cyclazocine has largely been relegated to research use, serving as a prototypical KOR agonist in pharmacological studies of opioid receptor function, addiction, and mood regulation.
Etymology/Origin
The name “cyclazocine” combines the prefix “cycl‑,” referring to the cyclic (ring‑containing) nature of the core morphinan scaffold, with the suffix “‑azocine,” a common designation for compounds containing an azocine (eight‑membered nitrogen‑bearing) ring system. The term was introduced by the pharmaceutical developers who first synthesized the molecule.
Characteristics
-
Chemical Structure: Cyclazocine is a bicyclic morphinan derivative with the IUPAC name (±)-8‑hydroxy‑14‑hydroxy‑13‑methoxy‑1,2,3,4,5,6‑hexahydro‑6‑methoxy‑4‑methyl‑3‑phenyl‑2‑[2‑(1‑pyrrolidinyl)ethyl]‑1H‑isoquinoline. It possesses a phenolic hydroxyl group and a tertiary amine side chain, features typical of many opioid ligands.
-
Pharmacodynamics:
- Kappa Opioid Receptor (KOR): High affinity agonist (K_i ≈ 0.2 nM). Activation of KOR produces analgesia, diuresis, and dysphoric effects.
- Mu Opioid Receptor (MOR): Low to moderate affinity partial agonist/antagonist (K_i ≈ 10 nM). This profile can attenuate the rewarding properties of full MOR agonists.
- Delta Opioid Receptor (DOR): Negligible activity.
-
Pharmacokinetics: In animal models, cyclazocine is rapidly absorbed after subcutaneous or intraperitoneal administration, reaches peak plasma concentrations within 15–30 minutes, and is metabolized primarily by hepatic CYP450 enzymes. The elimination half‑life is approximately 1–2 hours in rodents; human data are limited.
-
Effects and Side Effects: Analgesia comparable to morphine at equianalgesic doses, but accompanied by pronounced dysphoria, anxiety, and hallucination‑like phenomena in a dose‑dependent manner. These adverse central effects are typical of KOR agonism.
-
Legal and Regulatory Status: Cyclazocine is not scheduled under the United Nations Single Convention on Narcotic Drugs, but it is classified as a research chemical in many jurisdictions. It is not approved for clinical use in the United States, the European Union, or other major regulatory agencies.
-
Research Applications: Frequently employed in preclinical studies to:
- Elucidate KOR signaling pathways.
- Investigate the role of KOR in stress, depression, and addiction.
- Test the efficacy of KOR antagonists in reversing dysphoric states.
Related Topics
- Opioid Receptors – μ (MOR), κ (KOR), δ (DOR).
- Kappa‑Opioid Agonists – e.g., U‑50488, enadoline, salvinorin A.
- Mixed‑Action Opioids – compounds that act as partial agonists/antagonists at multiple opioid receptors (e.g., buprenorphine, nalorphine).
- Opioid‑Induced Dysphoria – psychological effects associated with KOR activation.
- Morphinan Chemistry – the class of compounds containing the tetracyclic morphinan scaffold, from which cyclazocine is derived.
Note: All pharmacological values are derived from peer‑reviewed literature and drug databases; where variability exists among studies, representative averages are presented.